Cleerly key facts
as of Oct 2026- Developer of a healthcare platform designed to create a new standard of care for coronary artery disease.
- It has raised $410.3M across 2 recorded rounds; the latest was Later Stage VC ($51.3M) in Nov 2024.
- Notable investors include General Catalyst, Impact Assets, Insight Partners (New York), Fidelity Management & Research Company, Battery Ventures — 23 tracked in total.
- 3 institutional filers report fund marks on Cleerly across 16 filings.
- Cleerly has filed 1 Form D with the SEC, most recently Dec 2024 ($51.3M sold to 10 investors).
- Status: Privately Held (backing).
- ·The complete investor list: 23 names
- ·Watch Cleerly: the Monday email on marks, rounds and moves
Institutional fund marks on Cleerly
3 filers · latest Jul 20263 SEC-registered funds reported 16 fair-value marks on Cleerly between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Cleerly funding rounds
2 roundsWho backs Cleerly
23+Recent activity
In the last 90 days, Cleerly's record added 1 institutional fund mark (latest period Jul 2026).
How much has Cleerly raised?
Cleerly has raised $410 million in total; 2 of its rounds are on record. The largest on record was a $51.3 million later-stage round in Nov 2024.
Cleerly has filed 1 Form D with the SEC, most recently in Dec 2024 ($51.3 million sold to 10 investors).
Institutional holders and vehicles
3 SEC-registered funds reported 16 fair-value marks on Cleerly between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Cleerly investors
23 investors are on record for Cleerly, including General Catalyst, Impact Assets, Insight Partners (New York) and Fidelity Management & Research Company. By type, the record holds 5 venture capital firms, 2 growth equity firms and 1 asset manager. The later-stage round in Nov 2024 drew 10 investors.
About Cleerly
Developer of a healthcare platform designed to create a new standard of care for coronary artery disease. The company's platform has a non-invasive approach that supports the understanding of plaques and offers quantification and characterization of plaque buildup in the heart arteries, enabling healthcare providers to drastically improve the identification of at-risk patients for early treatment and prevention of heart attacks cost-effectively.
- Industry
- Decision/Risk Analysis
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2016
- Employees
- 235
- Website
- cleerlyhealth.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.